Neurotrauma

$1.3 Billion Worldwide Intracranial Pressure (ICP) Monitoring Devices Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Infectious diseases, Health, Medical devices, Branches of biology, Neurotrauma, Medical signs, Intracranial pressure, Neurophysiology, Ventricular system, ICP

The "Intracranial Pressure (ICP) Monitoring Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intracranial Pressure (ICP) Monitoring Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Intracranial Pressure (ICP) Monitoring Devices estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$1.9 Billion by 2027, growing at a CAGR of 5.3% over the period 2020-2027.
  • Invasive, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$1.7 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $365 Million, While China is Forecast to Grow at 8.1% CAGR
    The Intracranial Pressure (ICP) Monitoring Devices market in the U.S. is estimated at US$365 Million in the year 2020.

Study: New Effective Way to Address Mild Traumatic Brain Injury via Telehealth

Retrieved on: 
Tuesday, July 27, 2021
Neurotrauma, Medical specialties, Clinical medicine, Medicine, Concussion, Traumatic brain injury, Brain damage, Post-concussion syndrome, Rivermead post-concussion symptoms questionnaire

SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- A study conducted at five military and Veterans hospitals has identified the first effective and highly-scalable intervention to address cognitive deficits that can persist for years after a mild Traumatic Brain Injury typically from concussion or blast exposure.

Key Points: 
  • SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- A study conducted at five military and Veterans hospitals has identified the first effective and highly-scalable intervention to address cognitive deficits that can persist for years after a mild Traumatic Brain Injury typically from concussion or blast exposure.
  • The intervention studied was the computerized brain training app BrainHQ , made by Posit Science , which was administered via telehealth in the study.
  • More than 413,000 members of the US military have been diagnosed with a Traumatic Brain Injury.
  • Of these, more than 82% are classified as mild TBI (mTBI), often called the signature injury of recent conflicts.

Planet TV Studios Presents the New Frontier Documentary Episode Featuring Cognitive FX

Retrieved on: 
Thursday, July 22, 2021
Neurotrauma, Medical specialties, Clinical medicine, Medicine, Concussion, Post-concussion syndrome

Premier brain injury treatment center, Cognitive FX, helps patients from around the world heal from post-concussion symptoms (PCS) using its state-of-the-art imaging technology and multidisciplinary treatment.

Key Points: 
  • Premier brain injury treatment center, Cognitive FX, helps patients from around the world heal from post-concussion symptoms (PCS) using its state-of-the-art imaging technology and multidisciplinary treatment.
  • Cognitive FX advances the way concussions are understood and treated and has seen thousands of patients from around the globe.
  • Planet TV Studios is a leading content creation company successful in films, television, documentaries, commercials, and docudramas.
  • For more information about Cognitive FX, please visit: https://www.cognitivefxusa.com
    For more information about the series, please visit https://planettvstudios.com or call Christian Alain at 888-210-4292 x100

ZOLL Medical Receives FDA Clearance for TBI Dashboard on Its Propaq M Monitor and Propaq MD Monitor/Defibrillator

Retrieved on: 
Wednesday, July 21, 2021
Technology, Other Defense, Contracts, Software, Hardware, Health, General Health, Data management, Defense, Neurotrauma, Medical specialties, Clinical medicine, Medicine, Medical emergencies, Intensive care medicine, Psychiatric diagnosis, Traumatic brain injury, TBI, ZOLL Medical Corporation, Asahi Kasei, ZOLL MEDICAL CORPORATION, ASAHI KASEI

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has received FDA 510(k) clearance to release the TBI Dashboard feature on its Propaq M monitor and Propaq MD monitor/defibrillator.

Key Points: 
  • ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has received FDA 510(k) clearance to release the TBI Dashboard feature on its Propaq M monitor and Propaq MD monitor/defibrillator.
  • TBI Dashboard provides clinical decision support for managing patients with TBI (traumatic brain injury) and was previously available on Propaq devices in international markets.
  • From the point of injury throughout the continuum of en-route care, ZOLL's Propaq M and Propaq MD monitor/defibrillators, now with TBI Dashboard capabilities, support rapid treatment and effective management of TBI patients.
  • TBI Dashboard, X Series, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.

Ian Burnstein Joins Wesana Health Board of Directors

Retrieved on: 
Friday, July 16, 2021
Medical specialties, Neurotrauma, Clinical medicine, Medicine, Burnstein, Traumatic brain injury, Neurology

TORONTO and CHICAGO, July 16, 2021 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (Wesana or the Company) (CSE: WESA), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the addition of Ian Burnstein to its Board of Directors.

Key Points: 
  • TORONTO and CHICAGO, July 16, 2021 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (Wesana or the Company) (CSE: WESA), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the addition of Ian Burnstein to its Board of Directors.
  • It was previously announced on July 14, 2021 that Mr. Burnstein was appointed to the Companys advisory board.
  • Wesana is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI).
  • Through extensive clinical research and academic partnerships, Wesana is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

United States Spinal Cord Injury Market and Competitive Landscape Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Health, Pharmaceutical, Branches of biology, Neurotrauma, Nervous system, Neuroscience, Medical emergencies, Spinal cord, Injuries, Spinal cord injury, Spinal traction

The "US Spinal Cord Injury Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Spinal Cord Injury Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Spinal Cord Injury Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Spinal Cord Injury pipeline products, Spinal Cord Injury epidemiology, Spinal Cord Injury market valuations and forecast, Spinal Cord Injury drugs sales and competitive landscape in the US.
  • Spinal Cord Injury pipeline: Find out the products in clinical trials for the treatment of Spinal Cord Injury by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Spinal Cord Injury drugs: Identify key products marketed and prescribed for Spinal Cord Injury in the US, including trade name, molecule name, and company
    Spinal Cord Injury drugs sales: Find out the sales revenues of Spinal Cord Injury drugs in the US
    Spinal Cord Injury market valuations: Find out the market size for Spinal Cord Injury drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Spinal Cord Injury drugs market share: Find out the market shares for key Spinal Cord Injury drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Spinal Cord Injury products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005473/en/

KANEKA CORPORATION: Sales Expansion of Brain Aneurysm Embolization Coils in the United States

Retrieved on: 
Friday, July 9, 2021
Health, Chemicals, Plastics, FDA, Medical devices, Surgery, Manufacturing, Other Manufacturing, Medical specialties, Neurosurgery, Cerebrovascular diseases, Branches of biology, Nervous system, Neurotrauma, Vascular diseases, Intracranial aneurysm, Aneurysm, Subarachnoid hemorrhage, Stroke, Kaneka Corporation

Inc., Kaneka intends to further expand the sales in the U.S. market from August 2021.

Key Points: 
  • Inc., Kaneka intends to further expand the sales in the U.S. market from August 2021.
  • Kaneka Medical America has been promoting the product at major stroke centers in the U.S., the worlds largest market.
  • It is deployed into the aneurysm through a catheter to prevent blood flow into the aneurysm.
  • A brain aneurysm is a bump that develops in an artery of the brain, and if it ruptures, it can cause subarachnoid hemorrhage.

Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Biology, Medical signs, Biomarkers, Neurotrauma, Biotechnology, Chemical pathology

DoD/MTEC previously awarded $1.9 million to Ischemix to fund preclinical research on CMX-2043 for TBI.

Key Points: 
  • DoD/MTEC previously awarded $1.9 million to Ischemix to fund preclinical research on CMX-2043 for TBI.
  • The successful preclinical efficacy results were achieved in measures of recognized blood biomarkers, MRI analysis and behavior.
  • We are excited to commence this important phase of the development of our proprietary drug candidate to treat TBI.
  • The Center for Disease Control reports that in the US in 2014, there were about 2.9 million TBI-related emergency department visits.

InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021

Retrieved on: 
Tuesday, July 6, 2021
Research, Science, Corporate finance, Injuries, Neurotrauma, Spinal cord, Spinal cord injury, Common stock, Proxy, Branches of biology, Economy, Articles

Stockholders holding common stock at the close of business on Monday, May 17th, 2021 are entitled to vote at the meeting, even if they have subsequently sold their shares.

Key Points: 
  • Stockholders holding common stock at the close of business on Monday, May 17th, 2021 are entitled to vote at the meeting, even if they have subsequently sold their shares.
  • Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.
  • InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology Company with a focus on treatment of spinal cord injuries.
  • Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties.

Allegheny Valley Hospital Now Providing Specialized Rehabilitative Care for Traumatic Brain Injury Patients

Retrieved on: 
Friday, June 25, 2021
Neurotrauma, Medical specialties, Clinical medicine, Medicine, Brain damage, Traumatic brain injury, Physical medicine and rehabilitation, Allegheny Health Network

PITTSBURGH, June 25, 2021 /PRNewswire-PRWeb/ --Under the direction of physiatrist Thomas Franz, MD, Allegheny Health Network's (AHN) Allegheny Valley Hospital now offers specialized rehabilitation for patients who have suffered traumatic brain injury.

Key Points: 
  • PITTSBURGH, June 25, 2021 /PRNewswire-PRWeb/ --Under the direction of physiatrist Thomas Franz, MD, Allegheny Health Network's (AHN) Allegheny Valley Hospital now offers specialized rehabilitation for patients who have suffered traumatic brain injury.
  • "I always remind my colleagues that if you've seen one brain injury, you've seen one brain injury," said Dr. Franz.
  • Although most brain injuries are the result of trauma, they may also be caused by stroke, meningitis or a tumor on the brain.
  • For more information about traumatic brain injury rehabilitation at Allegheny Valley Hospital, visit (412) DOCTORS or http://AHN.org .